Amer Zeidan, MBBS, MHS, is an Associate Professor of Medicine at Yale School of Medicine, New Haven, CT, as well as Director of Early Therapeutics Research and Director of Continuing Medical Education. Dr Zeidan is an internationally recognized expert in myeloid malignancies, particularly in the clinical management of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Dr Zeidan obtained his medical degree from the University of Jordan, Amman, Jordan, before completing his internal medicine residency at Rochester General Hospital, Rochester, NY. Dr Zeidan undertook a hematology/oncology fellowship and a clinical research fellowship in MDS at Johns Hopkins University, Baltimore, MD, where he also earned a Master of Health Science degree in Clinical Investigation. Dr Zeidan conducts extensive work in clinical trials. He has been a Principal Investigator and National Study Chair in several major trials, many focused on immunotherapy or novel combination therapy in myeloid malignancies. Dr Zeidan’s innovative work has earned him many awards throughout his career including the American Society of Clinical Oncology Young Investigator Award, the MDS Clinical Research Consortium Fellowship Award, the Leukemia & Lymphoma Society Scholar in Clinical Research Award, and the NCI’s Cancer Clinical Investigator Team Leadership Award. He has published extensively and serves on several editorial boards, including Blood Reviews and Leukemia and Lymphoma.
Speaking on novel therapies in MDS and AML
Dr Zeidan’s research focuses on the clinical management of MDS and AML. Much of his work is dedicated to the development of novel therapies, particularly immunotherapies and combination therapy. Dr Zeidan also has a keen interest in effectiveness and outcomes research, with the goal of understanding how patients benefit from existing treatments in the real world, compared to what is seen in the controlled trial setting.